<DOC>
	<DOCNO>NCT02353572</DOCNO>
	<brief_summary>This phase I/II trial study safety best dose melphalan bortezomib give prior autologous stem cell transplant see well work treat patient multiple myeloma . Drugs use chemotherapy , melphalan , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Bortezomib may help melphalan work well make cancer cell sensitive drug . Giving chemotherapy autologous hematopoietic stem cell transplant help kill cancer cell body help make room patient 's bone marrow new blood-forming cell ( stem cell ) grow . After treatment , stem cell collect patient 's blood store . More chemotherapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy . Giving melphalan together bortezomib prior autologous hematopoietic stem cell transplant may better treatment multiple myeloma .</brief_summary>
	<brief_title>Melphalan Bortezomib Prior Autologous Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>This phase I , dose-escalation study melphalan bortezomib follow phase II study . Patients receive melphalan intravenously ( IV ) continuously day -5 -2 bortezomib IV 3-5 second day -4 -1 . Patients also receive dexamethasone IV day -1 prior second dose bortezomib . Beginning two day completion melphalan infusion , patient undergo autologous hematopoietic stem cell transplant . Eligible patient may undergo second transplant 2-4 month completion first transplant . After completion study treatment , patient follow monthly least 1 year every 3-6 month thereafter .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients symptomatic active multiple myeloma require treatment , include whose prior smolder myeloma progress symptomatic disease require chemotherapy ; newly diagnose previously treat patient eligible study Presence quantifiable Mcomponent immunoglobulin G ( IgG ) , IgA , IgD , IgE and/or urinary kappa lambda light chain Bence Jones protein , order evaluate response ; nonsecretory patient eligible provided patient &gt; 20 % plasmacytosis multiple ( &gt; 3 ) focal plasmacytoma magnetic resonance imaging ( MRI ) diffuse hyperintense signal short tau inversion recovery ( STIR ) weight image Performance status 02 base Southwest Oncology Group ( SWOG ) criterion ; patient poor performance status ( 34 ) also eligible improve performance 02 No significant comorbid medical condition ; uncontrolled life threaten infection Patient evaluation do within 35 day prior registration ; sign informed consent obtain patient accordance institutional federal guideline Patients history recent ( &lt; 6 month ) myocardial infarction , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control significant cardiac arrhythmia , arrhythmia associate prolonged QT interval ; leave ventricular ejection fraction echocardiogram multi gate acquisition scan ( MUGA ) &lt; 45 % assess within 35 day prior study registration Patients history moderate severe chronic obstructive and/or restrictive pulmonary disease , force expiratory volume 1 second ( FEV1 ) force vital capacity ( FVC ) &lt; 50 % predicted value ; diffuse capacity lung carbon monoxide ( DLCO ) &lt; 50 % ; partial pressure oxygen ( P02 ) &lt; 70 mmHg Patients prior history malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free least three year Pregnant nursing woman ; woman childbearing potential must negative pregnancy document within one week registration ; women/men reproductive potential may participate unless agree use two form effective contraceptive method Human immunodeficiency virus ( HIV ) positive patient Transaminases &gt; 2 x normal value bilirubin &gt; 2 x normal value ; prior history chronic liver disease Patients renal failure dialysis Active uncontrolled infection History significant psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>